<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM9392</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-9392</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Атеросклероз периферических артерий и показатели низкоинтенсивного воспаления у пациентов с ишемической болезнью сердца и сахарным диабетом 2 типа</article-title><trans-title-group xml:lang="en"><trans-title>Peripheral arterial disease and indicators of low-grade inflammation in patients with coronary artery disease and type 2 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5902-3803</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Генкель</surname><given-names>Вадим Викторович</given-names></name><name name-style="western" xml:lang="en"><surname>Genkel</surname><given-names>Vadim V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент, кафедра пропедевтики внутренних болезней</p></bio><bio xml:lang="en"><p>assistant, Department of Internal Medicine</p></bio><email xlink:type="simple">henkel-07@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3900-9278</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никушкина</surname><given-names>Карина Викторовна</given-names></name><name name-style="western" xml:lang="en"><surname>Nikushkina</surname><given-names>Karina V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., в.н.с. НИИ иммунологии Южно-Уральского государственного медицинского университета</p></bio><bio xml:lang="en"><p>PhD, research institute of Immunology</p></bio><email xlink:type="simple">knikushkina81@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9595-4664</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никонова</surname><given-names>Танзиля Ильдаровна</given-names></name><name name-style="western" xml:lang="en"><surname>Nikonova</surname><given-names>Tansilla I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>м.н.с. НИИ иммунологии Южно-Уральского государственного медицинского университета</p></bio><bio xml:lang="en"><p>junior scientist researcher, research institute of Immunology</p></bio><email xlink:type="simple">nikonova_19750225@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7731-7730</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шапошник</surname><given-names>Игорь Иосифович</given-names></name><name name-style="western" xml:lang="en"><surname>Shaposhnik</surname><given-names>Igor I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующий кафедрой пропедевтики внутренних болезней Южно-Уральского государственного медицинского университета</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Heaf of Department of Internal Medicine</p></bio><email xlink:type="simple">shaposhnik@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;ФГБОУ ВО Южно-Уральский государственный медицинский университет Минздрава России&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;South-Ural State Medical University&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>23</day><month>08</month><year>2018</year></pub-date><volume>21</volume><issue>3</issue><fpage>178</fpage><lpage>185</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Генкель В.В., Никушкина К.В., Никонова Т.И., Шапошник И.И., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Генкель В.В., Никушкина К.В., Никонова Т.И., Шапошник И.И.</copyright-holder><copyright-holder xml:lang="en">Genkel V.V., Nikushkina K.V., Nikonova T.I., Shaposhnik I.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/9392">https://www.dia-endojournals.ru/jour/article/view/9392</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. Изучение низкоинтенсивного воспаления у пациентов с сахарным диабетом 2 типа (СД2) и атеросклеротическими сердечно-сосудистыми заболеваниями является актуальной проблемой, так как более глубокое понимание каскада воспалительных реакций, возможно, опосредующих тяжелое атеросклеротическое поражение различных сосудистых бассейнов у пациентов с СД, несет возможность внедрения в практику более совершенных диагностических и терапевтических подходов.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Изучить показатели низкоинтенсивного воспаления и атеросклеротическое поражение периферических артерий в их взаимосвязи у пациентов с ишемической болезнью сердца (ИБС) и СД2.</p></sec><sec><title>МЕТОДЫ</title><p>МЕТОДЫ. В исследование были включены 137 пациентов (77 мужчин и 60 женщин) с ИБС (средний возраст – 62,0 (57,0–66,0) лет). В первую группу были включены 67 пациентов с ИБС и СД2, во вторую – 70 с ИБС и без. Субклиническое воспаление оценивали по уровням высокочувствительного С-реактивного белка (вчСРБ), интерлейкинов (ИЛ): ИЛ-1β, ИЛ-6, ИЛ-8, ИЛ-10 и фактора некроза опухоли альфа (ФНО-α). Всем пациентам проводили дуплексное сканирование сонных артерий и артерий нижних конечностей (АНК).</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Пациенты с ИБС и СД2 отличались статистически значимо большими значениями стенозирования артерий каротидного бассейна и АНК. Выявлены прямые корреляционные связи между маркерами воспаления и степенью стенозирования бедренных и берцовых артерий, а также толщиной комплекса интима-медиа сонных и бедренных артерий. В группе пациентов с СД2 значения ИЛ-1β составляли 2,04 (0,98–2,52) пг/мл, что было значимо меньше в сравнении с пациентами 2-й группы – 2,43 (1,84–3,19) пг/мл (p=0,010). Значения ИЛ-6 также были статистически значимо ниже в 1-й группе пациентов – 1,84 (0,73–4,41) пг/мл против 3,73 (2,27–10,2) пг/мл в 1-й и 2-й группах соответственно (p=0,008). Доза метформина обратно коррелировала с уровнем ИЛ-6 (r=-0,314; p=0,003).</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Пациенты с ИБС и СД2 в сравнении с пациентами без СД отличались статистически значимо большими значениями стенозирования периферических артерий. Уровни ИЛ-1β и ИЛ-6 в группе пациентов с ИБС и СД2 были статистически значимо ниже в сравнении с пациентами без СД. Доза получаемого метформина обратно коррелировала с уровнем ИЛ-6.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: The study of low-grade inflammation in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular diseases is a pressing problem. A deeper understanding of the cascade of inflammatory reactions, possibly mediating the severe atherosclerotic lesions of various vascular pools in patients with diabetes, has the potential to introduce more sophisticated diagnostic and therapeutic approaches into practice.</p></sec><sec><title>AIM</title><p>AIM: To study the interrelation of low-grade inflammation and atherosclerosis of peripheral arteries in patients with coronary artery disease (CAD) and T2DM.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: The study included 137 patients (77 men and 60 women) with CAD. The average age of patients was 62.0 (57.0–66.0) years. The first group included 67 patients with CAD and T2DM, and the second group included 70 patients with CAD. Low-grade inflammation was assessed by the levels of high-sensitivity C-reactive protein, interleukin (IL)-1β, IL-6, IL-8, IL-10 and TNF-α. All patients underwent duplex scanning of carotid arteries and lower extremity arteries (LEAs).</p></sec><sec><title>RESULTS</title><p>RESULTS: Patients with CAD and T2DM showed significantly greater values of stenosis of carotid arteries and LEAs. Direct correlation was revealed between markers of inflammation and the degree of stenosis of the femoral and tibial arteries, as well as the intima-media thickness of the carotid and femoral arteries. In the group of patients with T2DM, the value of IL-1β was 2.04 (0.98–2.52) pg/mL, which was significantly less than 2.43 (1.84–3.19) pg/mL for patients in the second group (p = 0.010). The values of IL-6 were also significantly lower in the first group of patients, at 1.84 (0.73–4.41) pg/mL vs. 3.73 (2.27–10.2) pg/mL in the first and second groups, respectively (p = 0.008). The dose of metformin was inversely correlated with the level of IL-6 (r = −0.314, p = 0.003).</p></sec><sec><title>CONCLUSIONS</title><p>CONCLUSIONS: Patients with CAD and T2DM compared with patients without diabetes had significantly greater values of stenosis of peripheral arteries. The levels of IL-1β and IL-6 in the group of patients with CAD and T2DM were significantly lower in comparison with patients without diabetes. The dose of metformin was inversely correlated with the level of IL-6.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>атеросклероз периферических артерий</kwd><kwd>сахарный диабет</kwd><kwd>интерлейкин-6</kwd><kwd>интерлейкин-1β</kwd><kwd>метформин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>peripheral artery disease</kwd><kwd>diabetes mellitus</kwd><kwd>interleukin-6</kwd><kwd>interleukin-1β</kwd><kwd>metformin</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">ФГБОУ ВО ЮУГМУ Минздрава России</funding-statement><funding-statement xml:lang="en">South-Ural State Medical University</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(2):115-126. doi: 10.1056/NEJM199901143400207</mixed-citation><mixed-citation xml:lang="en">Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(2):115-126. doi: 10.1056/NEJM199901143400207</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ammirati E, Moroni F, Norata GD, et al. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015;2015:718329. doi: 10.1155/2015/718329</mixed-citation><mixed-citation xml:lang="en">Ammirati E, Moroni F, Norata GD, et al. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015;2015:718329. doi: 10.1155/2015/718329</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Soeki T, Sata M. Inflammatory Biomarkers and Atherosclerosis. Int Heart J. 2016;57(2):134-139. doi: 10.1536/ihj.15-346</mixed-citation><mixed-citation xml:lang="en">Soeki T, Sata M. Inflammatory Biomarkers and Atherosclerosis. Int Heart J. 2016;57(2):134-139. doi: 10.1536/ihj.15-346</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Boehme AK, McClure LA, Zhang Y, et al. Inflammatory Markers and Outcomes After Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study. Stroke. 2016;47(3):659-667. doi: 10.1161/STROKEAHA.115.012166</mixed-citation><mixed-citation xml:lang="en">Boehme AK, McClure LA, Zhang Y, et al. Inflammatory Markers and Outcomes After Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study. Stroke. 2016;47(3):659-667. doi: 10.1161/STROKEAHA.115.012166</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Беленькова Ю.А., Кашталап В.В., Каретникова В.Н., и др. Факторы воспаления, влияющие на прогноз у больных инфарктом миокарда с подъемом сегмента ST, подвергшихся чрескожным коронарным вмешательствам // Международный журнал интервенционной кардиоангиологии. – 2012. – №29. – C. 51-58. [Belenkova YA, Kashtalap VV, Karetnikova VN, et al. Inflammatory factors affecting prognosis in patients with myocardial infarction with ST-segment elevation undergoing percutaneous coronary interventions. International Journal of Interventional Cardioangiology. 2012;(29):51-58. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Беленькова Ю.А., Кашталап В.В., Каретникова В.Н., и др. Факторы воспаления, влияющие на прогноз у больных инфарктом миокарда с подъемом сегмента ST, подвергшихся чрескожным коронарным вмешательствам // Международный журнал интервенционной кардиоангиологии. – 2012. – №29. – C. 51-58. [Belenkova YA, Kashtalap VV, Karetnikova VN, et al. Inflammatory factors affecting prognosis in patients with myocardial infarction with ST-segment elevation undergoing percutaneous coronary interventions. International Journal of Interventional Cardioangiology. 2012;(29):51-58. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Xiong XD, Xiong WD, Xiong SS, et al. Research Progress on the Risk Factors and Outcomes of Human Carotid Atherosclerotic Plaques. Chin Med J (Engl). 2017;130(6):722-729. doi: 10.4103/0366-6999.201598</mixed-citation><mixed-citation xml:lang="en">Xiong XD, Xiong WD, Xiong SS, et al. Research Progress on the Risk Factors and Outcomes of Human Carotid Atherosclerotic Plaques. Chin Med J (Engl). 2017;130(6):722-729. doi: 10.4103/0366-6999.201598</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hameed I, Masoodi SR, Mir SA, et al. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes. 2015;6(4):598-612. doi: 10.4239/wjd.v6.i4.598</mixed-citation><mixed-citation xml:lang="en">Hameed I, Masoodi SR, Mir SA, et al. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes. 2015;6(4):598-612. doi: 10.4239/wjd.v6.i4.598</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Климонтов В.В., Тян Н.В., Фазуллина О.Н., и др. Клинические и метаболические факторы, ассоциированные с хроническим воспалением низкой интенсивности, у больных сахарным диабетом 2 типа // Сахарный диабет. – 2016. —Т. 19. – №4. – С. 295-302. [Klimontov VV, Tyan NV, Fazullina ON, et al. Clinical and metabolic factors associated with chronic low-grade inflammation in type 2 diabetic patients. Diabetes Mellitus. 2016;19(4):295-302. (In Russ.)] doi: 10.14341/dm7928</mixed-citation><mixed-citation xml:lang="en">Климонтов В.В., Тян Н.В., Фазуллина О.Н., и др. Клинические и метаболические факторы, ассоциированные с хроническим воспалением низкой интенсивности, у больных сахарным диабетом 2 типа // Сахарный диабет. – 2016. —Т. 19. – №4. – С. 295-302. [Klimontov VV, Tyan NV, Fazullina ON, et al. Clinical and metabolic factors associated with chronic low-grade inflammation in type 2 diabetic patients. Diabetes Mellitus. 2016;19(4):295-302. (In Russ.)] doi: 10.14341/dm7928</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Shen XH, Feng WM, et al. Analysis of Inflammatory Mediators in Prediabetes and Newly Diagnosed Type 2 Diabetes Patients. J Diabetes Res. 2016;2016:7965317. doi:10.1155/2016/7965317</mixed-citation><mixed-citation xml:lang="en">Wang Z, Shen XH, Feng WM, et al. Analysis of Inflammatory Mediators in Prediabetes and Newly Diagnosed Type 2 Diabetes Patients. J Diabetes Res. 2016;2016:7965317. doi:10.1155/2016/7965317</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamoto Y, Yamamoto H. RAGE-Mediated Inflammation, Type 2 Diabetes, and Diabetic Vascular Complication. Front Endocrinol (Lausanne). 2013;21(4):105. doi: 10.3389/fendo.2013.00105</mixed-citation><mixed-citation xml:lang="en">Yamamoto Y, Yamamoto H. RAGE-Mediated Inflammation, Type 2 Diabetes, and Diabetic Vascular Complication. Front Endocrinol (Lausanne). 2013;21(4):105. doi: 10.3389/fendo.2013.00105</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Freitas Lima LC, Braga VA, do Socorro de Franca Silva M, et al. Adipokines, diabetes and atherosclerosis: an inflammatory association. Front Physiol. 2015;6:304. doi: 10.3389/fphys.2015.00304</mixed-citation><mixed-citation xml:lang="en">Freitas Lima LC, Braga VA, do Socorro de Franca Silva M, et al. Adipokines, diabetes and atherosclerosis: an inflammatory association. Front Physiol. 2015;6:304. doi: 10.3389/fphys.2015.00304</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Puz P, Lasek-Bal A, Ziaja D, et al. Inflammatory markers in patients with internal carotid artery stenosis. Arch Med Sci. 2013;9:254-260. doi: 10.5114/aoms.2013.34533</mixed-citation><mixed-citation xml:lang="en">Puz P, Lasek-Bal A, Ziaja D, et al. Inflammatory markers in patients with internal carotid artery stenosis. Arch Med Sci. 2013;9:254-260. doi: 10.5114/aoms.2013.34533</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang B, Wang J, Xu Y, et al. Correlative association of interleukin-6 with intima media thickness: a meta-analysis. Int J Clin Exp Med. 2015;8(3):4731-4743.</mixed-citation><mixed-citation xml:lang="en">Zhang B, Wang J, Xu Y, et al. Correlative association of interleukin-6 with intima media thickness: a meta-analysis. Int J Clin Exp Med. 2015;8(3):4731-4743.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Signorelli SS, Fiore V, Malaponte G. Inflammation and peripheral arterial disease: the value of circulating biomarkers (Review). Int J Mol Med. 2014;33(4):777-783. doi: 10.3892/ijmm.2014.1657</mixed-citation><mixed-citation xml:lang="en">Signorelli SS, Fiore V, Malaponte G. Inflammation and peripheral arterial disease: the value of circulating biomarkers (Review). Int J Mol Med. 2014;33(4):777-783. doi: 10.3892/ijmm.2014.1657</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hazarika S, Annex BH. Biomarkers and Genetics in Peripheral Artery Disease. Clin Chem. 2017;63(1):236-244. doi:10.1373/clinchem.2016.263798</mixed-citation><mixed-citation xml:lang="en">Hazarika S, Annex BH. Biomarkers and Genetics in Peripheral Artery Disease. Clin Chem. 2017;63(1):236-244. doi:10.1373/clinchem.2016.263798</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Libby P, Hansson GK. Inflammation and Immunity in Diseases of the Arterial Tree: Players and Layers. Circ Res. 2015;116(2):307–311. doi: 10.1161/CIRCRESAHA.116.301313</mixed-citation><mixed-citation xml:lang="en">Libby P, Hansson GK. Inflammation and Immunity in Diseases of the Arterial Tree: Players and Layers. Circ Res. 2015;116(2):307–311. doi: 10.1161/CIRCRESAHA.116.301313</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009;19(8):521-524. doi: 10.1016/j.numecd.2009.07.005</mixed-citation><mixed-citation xml:lang="en">Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009;19(8):521-524. doi: 10.1016/j.numecd.2009.07.005</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lin GM, Chu KM, Han CL. Reverse epidemiology reflects C-reactive protein as a bystander of atherosclerosis in established systemic inflammation models. Int J Cardiol. 2011;146(3):422-423. doi:10.1016/j.ijcard.2010.10.094</mixed-citation><mixed-citation xml:lang="en">Lin GM, Chu KM, Han CL. Reverse epidemiology reflects C-reactive protein as a bystander of atherosclerosis in established systemic inflammation models. Int J Cardiol. 2011;146(3):422-423. doi:10.1016/j.ijcard.2010.10.094</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Бардымова Т.П., Протасов К.В., Цыреторова С.С., и др. Сахарный диабет 2-го типа и ишемическая болезнь сердца // Acta Biomedica Scientifica. – 2017. – Т. 2. – №1. – С. 100-106. [Bardymova TP, Protasov KV, Tsyretorova SS, et al. Type 2 diabetes mellitus and coronary heart disease. Acta Biomedica Scientifica. 2017;2(1):100-106. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Бардымова Т.П., Протасов К.В., Цыреторова С.С., и др. Сахарный диабет 2-го типа и ишемическая болезнь сердца // Acta Biomedica Scientifica. – 2017. – Т. 2. – №1. – С. 100-106. [Bardymova TP, Protasov KV, Tsyretorova SS, et al. Type 2 diabetes mellitus and coronary heart disease. Acta Biomedica Scientifica. 2017;2(1):100-106. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Петелина Т.И., Мусихина Н.А., Гапон Л.И., и соавт. Сравнительная характеристика параметров липидного спектра и маркеров сосудистого воспаления в группах пациентов со стабильной стенокардией при наличии и отсутствии сахарного диабета 2 типа // Сахарный диабет. – 2017. – Т. 20. – №3. – С. 194-200. [Petelina TI, Musikhina NA, Gapon LI, et al. Lipid profile and markers of vascular inflammation in patients with stable angina in the presence and absence of type 2 diabetes mellitus. Diabetes Mellitus. 2017;20(3):194-200. (In Russ.)] doi: 10.14341/7959</mixed-citation><mixed-citation xml:lang="en">Петелина Т.И., Мусихина Н.А., Гапон Л.И., и соавт. Сравнительная характеристика параметров липидного спектра и маркеров сосудистого воспаления в группах пациентов со стабильной стенокардией при наличии и отсутствии сахарного диабета 2 типа // Сахарный диабет. – 2017. – Т. 20. – №3. – С. 194-200. [Petelina TI, Musikhina NA, Gapon LI, et al. Lipid profile and markers of vascular inflammation in patients with stable angina in the presence and absence of type 2 diabetes mellitus. Diabetes Mellitus. 2017;20(3):194-200. (In Russ.)] doi: 10.14341/7959</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Руяткина Л.А., Руяткин Д.С. Многоплановые эффекты метформина у пациентов с сахарным диабетом 2 типа // Сахарный диабет. – 2017. – Т. 20. – №3. – С. 210-219. [Ruyatkina LA, Ruyatkin DS. Multidimensional effects of metformin in patients with type 2 diabetes. Diabetes Mellitus. 2017;20(3):210-219. (In Russ.)]. doi: 10.14341/dm2003458-64</mixed-citation><mixed-citation xml:lang="en">Руяткина Л.А., Руяткин Д.С. Многоплановые эффекты метформина у пациентов с сахарным диабетом 2 типа // Сахарный диабет. – 2017. – Т. 20. – №3. – С. 210-219. [Ruyatkina LA, Ruyatkin DS. Multidimensional effects of metformin in patients with type 2 diabetes. Diabetes Mellitus. 2017;20(3):210-219. (In Russ.)]. doi: 10.14341/dm2003458-64</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Xu X, Du C, Zheng Q, et al. Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. BMC Womens Health. 2014;14:93. doi: 10.1186/1472-6874-14-93</mixed-citation><mixed-citation xml:lang="en">Xu X, Du C, Zheng Q, et al. Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. BMC Womens Health. 2014;14:93. doi: 10.1186/1472-6874-14-93</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ciaraldi TP, Aroda V, Mudaliar SR, et al. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment. Metabolism. 2013;62:1587-1596. doi: 10.1016/j.metabol.2013.07.004</mixed-citation><mixed-citation xml:lang="en">Ciaraldi TP, Aroda V, Mudaliar SR, et al. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment. Metabolism. 2013;62:1587-1596. doi: 10.1016/j.metabol.2013.07.004</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Шаенко З.А., Расин М.С. Эффективность и безопасность метформина и пиоглитазона у пациентов с ишемической болезнью сердца и сахарным диабетом 2-го типа // Международный эндокринологический журнал. – 2015. – №2. – С. 66-70. [Shaenko ZA, Rasin MS. Efficiency and Safety of Metformine and Pioglitazone in Patients with Coronary Heart Disease and Diabetes Mellitus Type 2. International Journal of Endocrinology. 2015;(2):66-70. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Шаенко З.А., Расин М.С. Эффективность и безопасность метформина и пиоглитазона у пациентов с ишемической болезнью сердца и сахарным диабетом 2-го типа // Международный эндокринологический журнал. – 2015. – №2. – С. 66-70. [Shaenko ZA, Rasin MS. Efficiency and Safety of Metformine and Pioglitazone in Patients with Coronary Heart Disease and Diabetes Mellitus Type 2. International Journal of Endocrinology. 2015;(2):66-70. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W, Liu X, Ye S. Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;24(13):34. doi: 10.1186/s12950-016-0142-3</mixed-citation><mixed-citation xml:lang="en">Chen W, Liu X, Ye S. Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;24(13):34. doi: 10.1186/s12950-016-0142-3</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sobel BE, Hardison RM, Genuth S, et al. BARI 2D Investigators. Profibrinolytic, anti-thrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011;124:695-703. doi: 10.1161/CIRCULATIONAHA.110.014860</mixed-citation><mixed-citation xml:lang="en">Sobel BE, Hardison RM, Genuth S, et al. BARI 2D Investigators. Profibrinolytic, anti-thrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011;124:695-703. doi: 10.1161/CIRCULATIONAHA.110.014860</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Cameron AR, Morrison VL, Levin D, et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016;119(5):652-665. doi: 10.1161/CIRCRESAHA.116.308445</mixed-citation><mixed-citation xml:lang="en">Cameron AR, Morrison VL, Levin D, et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016;119(5):652-665. doi: 10.1161/CIRCRESAHA.116.308445</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Saisho Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205. doi: 10.2174/1871530315666150316124019</mixed-citation><mixed-citation xml:lang="en">Saisho Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205. doi: 10.2174/1871530315666150316124019</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hattori Y, Hattori K, Hayashi T. Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms. Diabetes. 2015;64(6):1907-1909. doi: 10.2337/db15-0090</mixed-citation><mixed-citation xml:lang="en">Hattori Y, Hattori K, Hayashi T. Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms. Diabetes. 2015;64(6):1907-1909. doi: 10.2337/db15-0090</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis. 2017;27(8):657-669. doi:10.1016/j.numecd.2017.04.009</mixed-citation><mixed-citation xml:lang="en">Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr Metab Cardiovasc Dis. 2017;27(8):657-669. doi:10.1016/j.numecd.2017.04.009</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
